8-K: ImmunityBio Reports Strong Q1 2026 Revenue Growth

ImmunityBio announced preliminary Q1 2026 net product revenue of approximately $44.2 million, a 168% increase year-over-year, driven by ANKTIVA adoption.

Summary

• ImmunityBio reported preliminary, unaudited net product revenue of approximately $44.2 million for the fiscal quarter ending March 31, 2026.
• This represents a significant year-over-year increase of approximately 168% compared to Q1 2025.
• The company also reported full-year 2025 net product revenue of $113 million, a 700% increase over full-year 2024.
• Sequential revenue growth was observed, with Q1 2026 revenue up 15% from Q4 2025 ($38.3 million).
• ANKTIVA has received approval or authorization in five regulatory jurisdictions, covering approximately 34 countries.
• The pivotal BCG-nave NMIBC CIS trial (QUILT-2.005) is fully enrolled, and a supplemental BLA submission is on track for 2026.
• The company ended Q1 2026 with an estimated $380.9 million in cash, cash equivalents, and marketable securities.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report due to significant revenue growth, strong product adoption, and promising clinical trial updates, despite the preliminary nature of the financial results.

Positives

• Net product revenue increased nearly 2.7 times year-over-year to a record $44.2 million in Q1 2026.
• Consistent quarter-over-quarter revenue growth since commercial launch, indicating continued adoption of ANKTIVA.
• ANKTIVA unit sales volume increased by 168% in Q1 2026 compared to Q1 2025.
• Full-year 2025 net product revenue reached $113 million, a 700% increase over full-year 2024.
• NCCN Clinical Practice Guidelines updated in March 2026 to include ANKTIVA plus BCG for specific NMIBC cases (Category 2A).
• Pivotal BCG-nave NMIBC CIS trial fully enrolled with adequate statistical power confirmed.
• Supplemental BLA submission for BCG-nave NMIBC CIS is on track for 2026.
• Company ended the quarter with a strong cash position of approximately $380.9 million.

Negatives

• The reported financial results are preliminary and unaudited, subject to change upon finalization of financial closing procedures.
• The preliminary estimates may differ materially from the actual results that will be reflected in the Form 10-Q.

Risks

• The preliminary financial results may differ from final reported results.
• Risks and uncertainties regarding participation, enrollment, and potential results from clinical trials.
• Uncertainty whether clinical trials will result in registrational pathways or if data will be accepted by regulatory agencies.
• Ability to fund ongoing and anticipated clinical trials.
• Potential delays in product availability and regulatory approvals.
• Ability to retain and hire key personnel.
• Need for additional financing to fund operations and complete development and commercialization.
• Potential product shortages or manufacturing disruptions impacting availability and timing.

Future Outlook

The company anticipates continued revenue growth and scaling in the U.S. market, alongside expansion into an increasing number of global markets. A supplemental BLA submission for the BCG-nave CIS indication is on track for 2026. The company is focused on advancing its pipeline across multiple solid and liquid tumor types.

Management Comments

• ANKTIVAs continued momentum reflects growing physician adoption and disciplined commercial execution. Following strong growth in 2025, we are focused on scaling in the U.S. and expanding across an increasing number of global markets.
• The sustained momentum of ANKTIVA reflects its growing commercial adoption in the BCG-unresponsive NMIBC CIS setting and feedback from treating urologists has been consistently positive. Across our clinical programs, we are seeing strong enrollment and growing investigator participation, supporting advancement of our broader pipeline.
• Full enrollment of our pivotal BCG-nave CIS with or without papillary disease trial, with IDMC confirmation of adequate statistical power further strengthen the expanding body of clinical evidence supporting ANKTIVA in the NMIBC bladder cancer setting.
• With our BCG-unresponsive NMIBC with papillary-only disease supplemental BLA now filed and our commitment to our pipeline development across multiple solid and liquid tumor types, we remain focused on advancing new treatment options for patients with bladder cancer and other indications.

Industry Context

StockSavvy.ai notes that ImmunityBio's strong revenue growth in Q1 2026, driven by ANKTIVA, aligns with the increasing focus on immunotherapies in oncology. The positive NCCN guideline update and progress in clinical trials suggest a favorable trajectory within the competitive bladder cancer treatment landscape.

Stakeholder Impact

• Shareholders: Potential for increased stock value due to strong revenue growth and positive clinical developments.
• Patients: Continued access to ANKTIVA, a treatment option for BCG-unresponsive NMIBC, with potential for expanded indications.
• Physicians: Growing adoption of ANKTIVA supported by positive clinical evidence and guideline inclusion.
• Regulators: Progress towards supplemental BLA submission indicates ongoing engagement with regulatory bodies.

Next Steps

• Finalize and report Q1 2026 operating results and financial position in the Form 10-Q.
• Submit supplemental BLA for BCG-nave NMIBC CIS in 2026.
• Continue scaling ANKTIVA sales in the U.S.
• Expand ANKTIVA's market presence across global jurisdictions.
• Advance pipeline development across multiple solid and liquid tumor types.

Key Dates

Recommendation

The preliminary results show strong growth and positive clinical progress, warranting a 'hold' as investors await final audited results and further details on the regulatory pathway and commercial expansion. The company's cash position is robust, but the preliminary nature of the financials and inherent risks in biotech development suggest caution.

Keywords

ImmunityBio, ANKTIVA, NMIBC, bladder cancer, biotechnology, oncology, revenue growth, clinical trials